FDA approves drug for inflammatory disease

Mar 06, 2008

The U.S. Food and Drug Administration approved the drug rilonacept to treat a group of rare diseases causing rash, fever, chills and joint pain.

Rilonacept, marketed under the name Arcalyst by Regeneron Pharmaceuticals, received marketing approval for the treatment of Cyropyrin-Associated Periodic Syndromes, including Familial Cold Auto-inflammatory Syndrome and Muckle-Wells Syndrome in adults and children ages 12 and older.

The familial cold syndrome is an "orphan" hereditary disease affecting only about 300 people in the United States, 90 percent of whom can trace their ancestry to a single person who came to America in the 1600s, the University of California's San Diego School of Medicine said Wednesday in a news release. Symptoms can be triggered at any time by exposure to cold temperatures, stress or exercise,

The drug is based on a discovery by Dr. Hal Hoffman, a professor at the medical school, who identified the genetic basis of the disease as a mutation that causes alterations in the protein cryopyrin.

Copyright 2008 by United Press International

Explore further: Drug research and development more efficient than expected

add to favorites email to friend print save as pdf

Related Stories

NASA satellite sees a warm winter in the Western US

54 minutes ago

While people in the eastern two-thirds of the U.S have been dealing with Arctic Air, the bulge in the Jet Stream over the eastern Pacific Ocean has been keeping the western third of the U.S. in warmer than ...

Korean tech start-ups offer life beyond Samsung

15 hours ago

As an engineering major at Seoul's Yonsei University, Yoon Ja-Young was perfectly poised to follow the secure, lucrative and socially prized career path long-favoured by South Korea's elite graduates.

Recommended for you

Drug research and development more efficient than expected

Feb 27, 2015

Drug R&D costs have increased substantially in recent decades, while the number of new drugs has remained fairly constant, leading to concerns about the sustainability of drug R&D and question about the factors that could ...

Use new meningitis vaccines only for outbreaks

Feb 26, 2015

(AP)—A U.S. panel on Thursday recommended that two new meningitis vaccines only be used for rare outbreaks, resisting tearful pleas to give it routinely to teens and college students.

New antibiotic avycaz approved

Feb 26, 2015

(HealthDay)—The combination antibiotic Avycaz (ceftazidime-avibactam) has been approved by the U.S. Food and Drug Administration to treat adults with complicated infections of the intra-abdominal area or urinary tract, ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.